Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor and Filgrastim Mobilization in Fanconi Anemia
NCT02931071Phase 2Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Sep 2013
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in Fanconi anemia (FA), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Toxicity of the mobilization procedure at 12 months. Started Sep 2013; status: completed.
02
Drugs
plerixafor
03
Conditions
Fanconi anemia (FA)
Beyond the preview
Go deeper on NCT02931071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931071.